These drugs are primarily used for preventing blood clots in patients who have undergone a procedure like stent placement after suffering a heart attack or those at high risk of forming blood clots.
Some key functions of P2Y12 inhibitors include reducing the risk of stent thrombosis and recurrent cardiovascular events post acute coronary syndromes. Rising prevalence of cardiovascular diseases such as heart attacks, strokes, and other conditions requiring procedures like balloon angioplasty and stent placement have increased the demand for antiplatelet drugs in the country. The increasing geriatric population also contributes as aging is a major risk factor for cardiovascular illnesses.
Key players operating in the U.S. P2Y12 inhibitors market are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation. The Global U.S. P2Y12 inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 To 2031.
Key Takeaways
Key players: Some major players are Eli Lilly and Company, Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co., Ltd., Sanofi, AstraZeneca plc and Boehringer Ingelheim International GmbH.
Key opportunities: U.S. P2Y12 Inhibitors Market Size Increasing awareness about cardiovascular conditions, rapid growth of the clinical trials sector, development of innovative drug delivery systems.
Global expansion: Key companies are expanding globally through partnerships, mergers and acquisitions to strengthen their market position and geographical footprint across world regions.
Market drivers: Rising cardiovascular disease burden, increasing usage of anticoagulants and antiplatelets, growing number of PCI procedures and stent placements, expansion of the geriatric population.
Market restraints: Patent expirations of blockbuster drugs, biosimilar competition, stringent regulatory approval process and safety issues regarding long-term use.
The market is driven by factors like rising prevalence of cardiovascular illnesses, growing geriatric population, increasing usage of anticoagulants post procedures. However, threats like patent expirations, biosimilar competition, regulatory challenges and safety issues could restrain market growth.
Segment Analysis
The U.S. P2Y12 inhibitors market is dominated by the clopidogrel bisulfate sub-segment owing to its widespread usage as an antiplatelet drug. Clopidogrel bisulfate is a thienopyridine class of antiplatelet drug which is used along with aspirin to prevent thrombus formation and reduce the rate of heart attacks or other serious problems in patients with coronary artery disease, recent stroke or heart attack. Its favorable safety profile and effectiveness have made it the preferred choice for physicians compared to other options.
Global Analysis
The North America region holds the largest share in the U.S. P2Y12 inhibitors market due to growing prevalence of cardiovascular diseases and increasing adoption of antiplatelet drugs within disease treatment regimens. According to the Centres for Disease Control and Prevention, cardiovascular disease is the leading cause of deaths in the United States with over 655,000 Americans dying from heart disease annually. In addition, presence of well-established healthcare and research infrastructure along with favorable reimbursement policies drive the demand for P2Y12 inhibitors in the region. Asia Pacific is expected to witness the fastest growth over the forecast period aided by rising healthcare spending, growing medical tourism industry and increasing incidence of cardiac conditions.
Get more insights on This Topic- U.S. P2Y12 Inhibitors Market
Comments
0 comment